Dianthus Therapeutics CEO Marino Garcia sells $17.9m in shares By Investing.com

Marino Garcia, CEO and President of Dianthus Therapeutics, Inc. (), sold a total of 166,000 shares of common stock on August 7, 2026, for a combined value of approximately $17.95 million. These sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Garcia on May 8, 2026. The timing coincides with the stock trading near its 52-week high of $114.55, following a remarkable 481% return over the past year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value, which may explain the strategic sale timing.

These transactions included the sale of 49,990 shares of common stock for a total of approximately $4,325,840, with prices ranging from $107.49 to $110.76 per share. Additionally, Mr. Garcia sold 116,000 shares for a total of approximately $13,619,610, at prices ranging from $107.96 to $108.72 per share.

Prior to these sales, Mr. Garcia acquired a total of 166,000 shares of common stock through the exercise of stock options. This included 40,000 shares acquired at an exercise price of $8.44 per share, totaling $337,600, and an additional 126,000 shares also acquired at $8.44 per share, totaling $1,063,440. The underlying stock options had a vesting schedule, with 25% vesting on November 1, 2022, and the remaining portion vesting in equal monthly installments over the subsequent three years, contingent on his continued service.

Following these reported transactions, Mr. Garcia directly held 65,292 shares of Dianthus Therapeutics common stock. He also held 160,004 shares underlying stock options.

In other recent news, Dianthus Therapeutics announced the initiation of its Phase 3 EMERGE trial, which will evaluate claseprubart in patients with generalized Myasthenia Gravis. The trial is set to enroll approximately 195 participants and involves a global, randomized, multicenter, placebo-controlled approach. Additionally, Raymond James raised its price target for Dianthus Therapeutics to $131 from $125, maintaining a Strong Buy rating. This update followed the company’s second-quarter 2026 earnings and the introduction of DNTH312, a new bifunctional fusion protein.

Raymond James also reiterated a Strong Buy rating based on new clinical trial data from the Phase 3 CAPTIVATE study, which showed a 75% responder rate for claseprubart in CIDP patients. Guggenheim maintained a Buy rating and a $200 price target for Dianthus, viewing Sanofi’s decision to halt a competing drug trial as beneficial for Dianthus’s program. TD Cowen echoed this sentiment by reiterating a Buy rating, noting that the halted trial was specific to Sanofi’s riliprubart and did not affect the outlook for Dianthus. These developments reflect ongoing confidence in Dianthus’s clinical programs and strategic direction.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.